ARO-AAT

ViewPoints Interview: Arrowhead’ Dr. Christopher Anzalone Shares Insights on the Data of ARO-AAT Presented at EASL 2021

In an interview with PharmaShots, Dr. Christopher Anzalone, President and CEO at Arrowhead shared his views on the interim 48-week data from the P-II AROAAT2002 study evaluates the safety and PD effects of ARO-AAT for the treatment of liver disease due to AATD Shots: The P-II AROAAT2002 study evaluated the safety & PD effects of …

ViewPoints Interview: Arrowhead’ Dr. Christopher Anzalone Shares Insights on the Data of ARO-AAT Presented at EASL 2021 Read More »

Takeda strikes $1B RNAi deal with Arrowhead Pharmaceuticals

The companies will partner on development and commercialization of ARO-AAT, Arrowhead’s Phase II RNA-interference drug for alpha-1 antitrypsin-associated liver disease, a rare genetic disorder. An analyst wrote that the deal makes sense given Takeda’s position in the AAT-augmentation therapy market.